Latest news with #PIK3CA-mutated
Gulf Today
02-06-2025
- Health
- Gulf Today
New breast cancer therapy can slow advance of disease, prolong survival
A new triple therapy for aggressive, advanced breast cancer slows the progression of the disease, delays the need for further chemotherapy and helps patients live longer, research revealed. The combination treatment is made up of two targeted drugs: inavolisib and palbociclib, and the hormone therapy fulvestrant. It improved overall survival by an average of seven months, compared with the patients in the control group, who were given palbociclib and fulvestrant. It also delayed progression of the disease by 17.2 months, on average, compared with 7.3 months in the control group, and patients taking inavolisib were able to delay subsequent chemotherapy treatment by almost two years longer than the patients in the control group. The results of the study, funded by Roche, were presented at the American Society of Clinical Oncology (Asco) annual meeting in Chicago and published in the New England Journal of Medicine. The international trial involved 325 patients from 28 countries, including the US, UK, Australia, Singapore, Brazil, France and Germany. Experts said it demonstrated the potential of the triple therapy for targeting PIK3CA-mutated HR+, HER2- breast cancer - a common form of the disease. About 70 percent of patients have HR+, HER2- breast cancer. PIK3CA mutations are found in 35 to 40 percent of HR+ breast cancers, and are linked to tumour growth, disease progression and treatment resistance. "The INAVO120 trial has identified a targeted treatment regimen that meaningfully improves survival in patients with untreated PIK3CA-mutated hormone receptor-positive metastatic breast cancer - a big step forward for these patients,' said Dr Jane Lowe Meisel, Co-Director of Breast Medical Oncology at Winship Cancer Institute of Emory University, and an Asco expert in breast cancer. The results also showed a substantial shrinking in cancer growth in about 62.7 percent of patients in the triple therapy group compared with 28 percent in the control group. Dr. Simon Vincent, Director of Research, support and influencing at Breast Cancer Now, said the findings were a "significant breakthrough'. Dr. Nisharnthi Duggan, a research information manager at Cancer Research UK, said, "The trial showed that adding inavolisib to targeted treatment plans improved survival. On top of this, it also delayed the progression of people's cancer and the need for chemotherapy, which could improve quality of life. We hope that more research like this will help to give people kinder cancer treatment options, and more time with their loved ones.' In the trial, more than half of the patients had disease that had already spread to three or more organs. The researchers used circulating tumour DNA (ctDNA) liquid biopsy blood tests to determine whether patients had a PIK3CA mutation. Participants were then allocated to receive either the inavolisib-based regimen or a combination of palbociclib, fulvestrant and a dummy pill. The new drug inavolisib works by blocking the activity of the PIK3CA protein. The inavolisib combination was generally well tolerated with only a few patients experiencing side-effects that led them to discontinue the treatment. Nick Turner, Professor of Molecular Oncology at the Institute of Cancer Research, London, and consultant medical oncologist at the Royal Marsden NHS Foundation Trust, led a UK arm of the trial. "The key findings from this study showed that the inavolisib-based therapy not only helped patients live longer but it more than doubled the time before their cancer progressed or worsened. It also gave them more time before needing subsequent chemotherapy which we know is something that patients really fear and want to delay for as long as possible," he stated. WAM
Business Insider
02-06-2025
- Business
- Business Insider
Genentech announces final results from OS analysis of Phase III INAVO120 study
Genentech, a member of the Roche (RHHBY) Group, announced positive final results from the overall survival, OS, analysis of the Phase III INAVO120 study. These data showed Itovebi, in combination with palbociclib and fulvestrant, reduced the risk of death by more than 30% compared with palbociclib and fulvestrant alone. This represents a statistically significant and clinically meaningful improvement in overall survival for people with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The results are being presented in an oral session at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting and simultaneously published in the New England Journal of Medicine, NEJM. The Itovebi-based regimen demonstrated a meaningful OS benefit compared with palbociclib and fulvestrant alone. The median OS was 34.0 months for people in the Itovebi arm, compared with 27.0 months in the palbociclib and fulvestrant arm. The benefit seen in delaying cancer progression was maintained in the updated analysis, with the Itovebi-based regimen showing a consistent improvement in median progression free survival of 17.2 months versus 7.3 months in the comparator arm. Confident Investing Starts Here:
ITV News
31-05-2025
- Health
- ITV News
New three-drug therapy helps women with aggressive breast cancer live longer, trial shows
A new three-drug combination could help women with a common form of aggressive breast cancer live longer, research suggests. The treatment could also delay the need for gruelling chemotherapy, according to a trial. If approved by the NHS, it could help thousands of patients every year. Researchers are hopeful the combination could become the 'new go-to option' for women with PIK3CA-mutated hormone receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer. This mutation in the PIK3CA gene causes cells to divide and replicate uncontrollably. The final results from the INAVO120 study, led by experts at The Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust, have been published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Professor Nick Turner said: "These results give us confidence that this treatment could become the new go-to option for patients who have HR+, HER2- breast cancer with a PIK3CA mutation, as it has shown significant improvements in both survival and quality of life." The trial included 325 patients from across 28 countries. More than half had metastatic breast cancer that had spread to three or more organs, and the majority had already had chemotherapy. What is the three-drug therapy? Researchers used a blood test known as a liquid biopsy, which detects tumour DNA in the blood, to test for the PIK3CA mutation. Of the total, 161 were given a three-drug combination comprising two targeted drugs – palbociclib, a type of cancer growth blocker, and a new drug called inavolisib, which blocks the activity of the PI3K protein – as well as the hormone therapy fulvestrant. The placebo group, which included 164 patients, was given a dummy pill plus palbociclib and fulvestrant. The study found the median overall survival in the inavolisib group was 34 months, compared with 27 months in the placebo group. The three-drug therapy also delayed disease progression by 17.2 months, compared with 7.3 months in the placebo group, with patients also able to delay chemotherapy treatment by almost two years longer. The latest results come after previous analysis of the study, published in October, showed the three-drug therapy delayed disease progression by an average of 15 months compared with 7.3 months in the placebo group. Lead author Nick Turner, a professor of molecular oncology at The Institute of Cancer Research, London, and consultant medical oncologist at The Royal Marsden NHS Foundation Trust, said: 'The key findings from this study showed that the inavolisib-based therapy not only helped patients live longer but it more than doubled the time before their cancer progressed or worsened. 'It also gave them more time before needing subsequent chemotherapy, which we know is something that patients really fear and want to delay for as long as possible. 'These results give us confidence that this treatment could become the new go-to option for patients who have HR+, HER2- breast cancer with a PIK3CA mutation, as it has shown significant improvements in both survival and quality of life.' How many women could this help? It is estimated that about 55,000 women are diagnosed with breast cancer in the UK every year, some 70% of whom will have HR+, HER2- breast cancer. PIK3CA mutations are found in 35-40% of HR+ breast cancers. The three-drug therapy of inavolisib, palbociclib and fulvestrant is not approved in the UK. However, the combination of palbociclib and fulvestrant has been available as an option for patients with certain types of breast cancer on the NHS since 2022. Professor Kristian Helin, chief executive of The Institute of Cancer Research, London, said: "This research demonstrates how this triple combination approach effectively shuts down cancer's escape routes, giving people with metastatic breast cancer the opportunity to live well for longer. He added: 'If we are to continue improving cancer survival rates, we need to tackle treatment resistance head on. 'This research demonstrates how this triple combination approach effectively shuts down cancer's escape routes, giving people with metastatic breast cancer the opportunity to live well for longer. 'One of the challenges with combination therapies is ensuring the right drug dosages and understanding their individual effects. 'It is extremely encouraging that this study not only demonstrates the effectiveness of this approach but also shows that the therapy was generally well tolerated by patients.'
The Herald Scotland
31-05-2025
- Health
- The Herald Scotland
Three-drug therapy helps women with aggressive breast cancer live longer
Researchers are hopeful the combination could become the 'new go-to option' for women with PIK3CA-mutated hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer. This mutation in the PIK3CA gene causes cells to divide and replicate uncontrollably. The final results from the INAVO120 study, led by experts at The Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust, have been published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The trial included 325 patients from across 28 countries. More than half had metastatic breast cancer that had spread to three or more organs and the majority had already had chemotherapy. Researchers used a blood test known as a liquid biopsy, which detects tumour DNA in the blood, to test for the PIK3CA mutation. Of the total, 161 were given a three-drug combination comprising two targeted drugs – palbociclib, a type of cancer growth blocker, and a new drug called inavolisib, which blocks the activity of the PI3K protein – as well as the hormone therapy fulvestrant. The placebo group, which included 164 patients, was given a dummy pill plus palbociclib and fulvestrant. The study found the median overall survival in the inavolisib group was 34 months, compared with 27 months in the placebo group. The three-drug therapy also delayed disease progression by 17.2 months, compared with 7.3 months in the placebo group, with patients also able to delay chemotherapy treatment by almost two years longer. The latest results come after previous analysis of the study, published in October, showed the three-drug therapy delayed disease progression by an average of 15 months compared with 7.3 months in the placebo group. Lead author Nick Turner, a professor of molecular oncology at The Institute of Cancer Research, London, and consultant medical oncologist at The Royal Marsden NHS Foundation Trust, said: 'The key findings from this study showed that the inavolisib-based therapy not only helped patients live longer but it more than doubled the time before their cancer progressed or worsened. 'It also gave them more time before needing subsequent chemotherapy which we know is something that patients really fear and want to delay for as long as possible. 'These results give us confidence that this treatment could become the new go-to option for patients who have HR+, HER2- breast cancer with a PIK3CA mutation, as it has shown significant improvements in both survival and quality of life.' It is estimated that about 55,000 women are diagnosed with breast cancer in the UK every year, some 70% of whom will have HR+, HER2- breast cancer. PIK3CA mutations are found in 35-40% of HR+ breast cancers. The three-drug therapy of inavolisib, palbociclib and fulvestrant is not approved in the UK. However, the combination of palbociclib and fulvestrant has been available as an option for patients with certain types of breast cancer on the NHS since 2022. Prof Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'If we are to continue improving cancer survival rates, we need to tackle treatment resistance head on. 'This research demonstrates how this triple combination approach effectively shuts down cancer's escape routes, giving people with metastatic breast cancer the opportunity to live well for longer. 'One of the challenges with combination therapies is ensuring the right drug dosages and understanding their individual effects. 'It is extremely encouraging that this study not only demonstrates the effectiveness of this approach but also shows that the therapy was generally well tolerated by patients.' Reacting to the findings, Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said: 'This is a significant breakthrough and we're proud that it builds on a series of discoveries that our funded scientists have been making at the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London, since it opened 25 years ago. 'We now hope to see this new combination therapy can be licensed by the MHRA (Medicines and Healthcare Products Regulatory Agency) and assessed by Nice (the National Institute for Health and Care Excellence) and the Scottish Medicine Council as soon as possible so that it can reach the NHS patients who could benefit from it.'
Western Telegraph
31-05-2025
- Health
- Western Telegraph
Three-drug therapy helps women with aggressive breast cancer live longer
The treatment could also delay the need for gruelling chemotherapy, according to a trial. Researchers are hopeful the combination could become the 'new go-to option' for women with PIK3CA-mutated hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer. This mutation in the PIK3CA gene causes cells to divide and replicate uncontrollably. The final results from the INAVO120 study, led by experts at The Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust, have been published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. These results give us confidence that this treatment could become the new go-to option for patients who have HR+, HER2- breast cancer with a PIK3CA mutation, as it has shown significant improvements in both survival and quality of life Prof Nick Turner The trial included 325 patients from across 28 countries. More than half had metastatic breast cancer that had spread to three or more organs and the majority had already had chemotherapy. Researchers used a blood test known as a liquid biopsy, which detects tumour DNA in the blood, to test for the PIK3CA mutation. Of the total, 161 were given a three-drug combination comprising two targeted drugs – palbociclib, a type of cancer growth blocker, and a new drug called inavolisib, which blocks the activity of the PI3K protein – as well as the hormone therapy fulvestrant. The placebo group, which included 164 patients, was given a dummy pill plus palbociclib and fulvestrant. The study found the median overall survival in the inavolisib group was 34 months, compared with 27 months in the placebo group. The three-drug therapy also delayed disease progression by 17.2 months, compared with 7.3 months in the placebo group, with patients also able to delay chemotherapy treatment by almost two years longer. The latest results come after previous analysis of the study, published in October, showed the three-drug therapy delayed disease progression by an average of 15 months compared with 7.3 months in the placebo group. Lead author Nick Turner, a professor of molecular oncology at The Institute of Cancer Research, London, and consultant medical oncologist at The Royal Marsden NHS Foundation Trust, said: 'The key findings from this study showed that the inavolisib-based therapy not only helped patients live longer but it more than doubled the time before their cancer progressed or worsened. 'It also gave them more time before needing subsequent chemotherapy which we know is something that patients really fear and want to delay for as long as possible. 'These results give us confidence that this treatment could become the new go-to option for patients who have HR+, HER2- breast cancer with a PIK3CA mutation, as it has shown significant improvements in both survival and quality of life.' It is estimated that about 55,000 women are diagnosed with breast cancer in the UK every year, some 70% of whom will have HR+, HER2- breast cancer. PIK3CA mutations are found in 35-40% of HR+ breast cancers. This research demonstrates how this triple combination approach effectively shuts down cancer's escape routes, giving people with metastatic breast cancer the opportunity to live well for longer Prof Kristian Helin The three-drug therapy of inavolisib, palbociclib and fulvestrant is not approved in the UK. However, the combination of palbociclib and fulvestrant has been available as an option for patients with certain types of breast cancer on the NHS since 2022. Prof Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'If we are to continue improving cancer survival rates, we need to tackle treatment resistance head on. 'This research demonstrates how this triple combination approach effectively shuts down cancer's escape routes, giving people with metastatic breast cancer the opportunity to live well for longer. 'One of the challenges with combination therapies is ensuring the right drug dosages and understanding their individual effects. 'It is extremely encouraging that this study not only demonstrates the effectiveness of this approach but also shows that the therapy was generally well tolerated by patients.' Reacting to the findings, Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said: 'This is a significant breakthrough and we're proud that it builds on a series of discoveries that our funded scientists have been making at the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London, since it opened 25 years ago. 'We now hope to see this new combination therapy can be licensed by the MHRA (Medicines and Healthcare Products Regulatory Agency) and assessed by Nice (the National Institute for Health and Care Excellence) and the Scottish Medicine Council as soon as possible so that it can reach the NHS patients who could benefit from it.'
